Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
NRGX Gene therapy
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] News for 'NRGX' - (DJ Neurologix To Conduct Added Preclinical Study On Epilepsy Drug) DOW JONES NEWSWIRES Neurologix Inc. (NRGX) will conduct an additional preclinical study in non-human primates of a gene therapy, according to a document filed Thursday with the Securities and Exchange Commission. The additional study is the result of recent comments from, and discussions with, the Food and Drug Administration about its investigational new drug application for a Phase I clinical trial in temporal lobe epilepsy. Neurologix said the study will be designed to confirm the safety of the administration and use of the adeno-associated virus expressing "Neuropeptide Y." The biotech company, which is engaged in the research and development of innovative gene therapies for the brain and central nervous systems, plans to work closely with the FDA to design a protocol with respect to this additional preclinical study. The beginning of its Phase I clinical trial will depend on the successful completion of this additional preclinical study, the filing said. At the present time, the company said it doesn't expect that the study will result in significant changes to the protocol submitted to the FDA for the Phase I clinical trial. Shares of the company's stock closed Wednesday at $1.10. -Chad Clinton, Dow Jones Newswires; 202-862-1349; chad.clinton*dowjones.com (END) Dow Jones Newswires January 24, 2008 07:25 ET (12:25 GMT) Copyright (c) 2008 Dow Jones & Company, Inc.- - 07 25 AM EST 01-24-08 Source: DJ Broad Tape [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2